about
The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indicationsRetinoic acid-induced differentiation increases the rate of oxygen consumption and enhances the spare respiratory capacity of mitochondria in SH-SY5Y cells.Transcription factors as therapeutic targets in lymphoid malignancies.Phototherapy of mycosis fungoides.Cutaneous T cell lymphoma: update on treatment.Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.The use of growth factors to modulate the activities of antigen-specific CD8+ T cells in vitro.Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma.Retinoic Acid Negatively Impacts Proliferation and MCTC Specific Attributes of Human Skin Derived Mast Cells, but Reinforces Allergic Stimulability.Acute hyperkeratotic and desquamative reaction in a patient with Sézary syndrome treated with bexarotene.Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.Treatment of cutaneous T-cell lymphoma with oral alitretinoin.Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group
P2860
Q33746059-8C93E8B7-45A3-4346-8043-DE721DE9DC15Q35975751-1DE174B9-0478-4005-B60C-FACB4C28EF34Q37008654-F1091E97-9041-4DF7-8AAB-FDB889786E12Q37851562-18D0FA6C-EC51-41BD-A0AC-869BF397F8B2Q38036396-F8CAA7AF-E796-47AA-AFD1-5257FA69D09AQ38096061-FD231724-4F0C-4D4D-9D54-58A13B3DF615Q38859341-F6C21F64-A38C-4327-AE92-E6F18B7BA55BQ39004668-CA244BF3-F743-420A-91B0-BD608F193B29Q39253408-38932248-B28C-4B32-84E9-1782B0CA4E4DQ39477666-480E3B14-D942-4948-92F6-4701A27B79E0Q42105965-70B0CE95-D3B0-463B-B440-79B6E3D998A6Q42293330-F91E4189-0639-410D-A993-8D5CAE704F67Q46758036-5AF9316F-F000-46D8-A61E-05602C7023D5Q48103683-1A91FB6D-5E78-46E3-B819-C6F04286D253Q50556792-CDA600C4-F2C1-4E34-9DC4-9A298FF9DB95Q51316502-1546981B-2241-486B-9EFD-511F7DB2A964Q58801965-1125F779-E263-47EE-9DF4-207BE4432120
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Treatment of cutaneous T-cell lymphoma with retinoids.
@ast
Treatment of cutaneous T-cell lymphoma with retinoids.
@en
type
label
Treatment of cutaneous T-cell lymphoma with retinoids.
@ast
Treatment of cutaneous T-cell lymphoma with retinoids.
@en
prefLabel
Treatment of cutaneous T-cell lymphoma with retinoids.
@ast
Treatment of cutaneous T-cell lymphoma with retinoids.
@en
P2860
P1433
P1476
Treatment of cutaneous T-cell lymphoma with retinoids.
@en
P2093
Chunlei Zhang
Madeleine Duvic
P2860
P304
P356
10.1111/J.1529-8019.2006.00083.X
P577
2006-09-01T00:00:00Z